Assertio Therapeutics, Inc. (ASRT): Price and Financial Metrics
ASRT Price/Volume Stats
| Current price | $6.20 | 52-week high | $8.01 |
| Prev. close | $6.20 | 52-week low | $2.07 |
| Day low | $6.08 | Volume | 399,632 |
| Day high | $6.24 | Avg. volume | 2,008,712 |
| 50-day MA | $6.32 | Dividend yield | N/A |
| 200-day MA | $4.28 | Market Cap | 345.34M |
ASRT Stock Price Chart Interactive Chart >
ASRT POWR Grades
- Value is the dimension where ASRT ranks best; there it ranks ahead of 97.27% of US stocks.
- The strongest trend for ASRT is in Sentiment, which has been heading down over the past 179 days.
- ASRT ranks lowest in Stability; there it ranks in the 3rd percentile.
ASRT Stock Summary
- With a price/earnings ratio of 3.77, ASSERTIO HOLDINGS INC P/E ratio is greater than that of about just 7.37% of stocks in our set with positive earnings.
- With a year-over-year growth in debt of -47.47%, ASSERTIO HOLDINGS INC's debt growth rate surpasses just 6.17% of about US stocks.
- In terms of volatility of its share price, ASRT is more volatile than 89.45% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to ASSERTIO HOLDINGS INC are BKSY, AMK, CUEN, GURE, and MEC.
- Visit ASRT's SEC page to see the company's official filings. To visit the company's web site, go to www.assertiotx.com.
ASRT Valuation Summary
- ASRT's price/sales ratio is 2.3; this is 4.55% higher than that of the median Healthcare stock.
- ASRT's price/earnings ratio has moved up 8.7 over the prior 243 months.
Below are key valuation metrics over time for ASRT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ASRT | 2023-05-23 | 2.3 | 1.5 | 3.8 | 15.0 |
| ASRT | 2023-05-22 | 2.4 | 1.6 | 4.0 | 16.0 |
| ASRT | 2023-05-19 | 2.5 | 1.6 | 4.2 | 16.7 |
| ASRT | 2023-05-18 | 2.4 | 1.6 | 4.1 | 16.1 |
| ASRT | 2023-05-17 | 2.4 | 1.6 | 4.1 | 16.2 |
| ASRT | 2023-05-16 | 2.3 | 1.5 | 3.9 | 15.5 |
ASRT Growth Metrics
- Its year over year net income to common stockholders growth rate is now at 104.99%.
- The 3 year net income to common stockholders growth rate now stands at 128.87%.
- Its 2 year net income to common stockholders growth rate is now at 102%.
The table below shows ASRT's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 139.209 | 56.032 | 25.678 |
| 2022-06-30 | 130.469 | 50.641 | 25.241 |
| 2022-03-31 | 120.711 | 37.175 | 3.238 |
| 2021-12-31 | 111.014 | 5.523 | -1.281 |
| 2021-09-30 | 107.86 | -4.59 | -30.241 |
| 2021-06-30 | 116.953 | -23.675 | -44.5 |
ASRT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ASRT has a Quality Grade of C, ranking ahead of 35.61% of graded US stocks.
- ASRT's asset turnover comes in at 0.367 -- ranking 129th of 680 Pharmaceutical Products stocks.
- NOVN, ARWR, and RIOT are the stocks whose asset turnover ratios are most correlated with ASRT.
The table below shows ASRT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.367 | 0.819 | -1.136 |
| 2021-03-31 | 0.343 | 0.800 | -1.673 |
| 2020-12-31 | 0.354 | 0.813 | -0.761 |
| 2020-09-30 | 0.380 | 0.884 | -1.944 |
| 2020-06-30 | 0.337 | 0.927 | -1.098 |
| 2020-03-31 | 0.332 | 0.957 | -0.485 |
ASRT Price Target
For more insight on analysts targets of ASRT, see our ASRT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $6.20 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Assertio Therapeutics, Inc. (ASRT) Company Bio
Assertio Therapeutics, Inc. (formerly DepoMed) develops products for pain and other central nervous system conditions in the United States. The company was founded in 1995 and is focused in Newark, California.
Latest ASRT News From Around the Web
Below are the latest news stories about ASSERTIO HOLDINGS INC that investors may wish to consider to help them evaluate ASRT as an investment opportunity.
Does Assertio Holdings (NASDAQ:ASRT) Deserve A Spot On Your Watchlist?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even... |
Assertio Holdings First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsAssertio Holdings ( NASDAQ:ASRT ) First Quarter 2023 Results Key Financial Results Revenue: US$42.5m (up 16% from 1Q... |
Q1 2023 Assertio Holdings Inc Earnings CallQ1 2023 Assertio Holdings Inc Earnings Call |
Assertio Reports First Quarter 2023 Financial Results, Raises Full Year 2023 OutlookNet Product Sales Increase 18% Year-Over-Year Raises Full Year Outlook to Net Product Sales of $157 to $167 Million, Adjusted EBITDA $90 to $98 Million To Acquire Spectrum Pharmaceuticals in All Stock and CVR Transaction, Expected to be Significantly Accretive to Adjusted EPS and Operating Cash Flow in 2024 LAKE FOREST, Ill., May 09, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products t |
Assertio Holdings, Inc.'s (NASDAQ:ASRT) largest shareholders are individual investors with 58% ownership, institutions own 40%Key Insights The considerable ownership by individual investors in Assertio Holdings indicates that they collectively... |
ASRT Price Returns
| 1-mo | 0.81% |
| 3-mo | 4.03% |
| 6-mo | 67.57% |
| 1-year | 100.00% |
| 3-year | 55.72% |
| 5-year | -76.19% |
| YTD | 44.19% |
| 2022 | 97.25% |
| 2021 | 52.40% |
| 2020 | -71.39% |
| 2019 | -65.37% |
| 2018 | -55.16% |
Continue Researching ASRT
Here are a few links from around the web to help you further your research on Assertio Therapeutics Inc's stock as an investment opportunity:Assertio Therapeutics Inc (ASRT) Stock Price | Nasdaq
Assertio Therapeutics Inc (ASRT) Stock Quote, History and News - Yahoo Finance
Assertio Therapeutics Inc (ASRT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...